| Richard Schmitt, MD | |
|
3 Erie Ct, Oak Park, IL 60302-2519 | |
| (708) 383-6200 | |
| Not Available |
| Full Name | Richard Schmitt |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 41 Years |
| Location | 3 Erie Ct, Oak Park, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154346534 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 01034535A (Indiana) | Secondary |
| 207P00000X | Emergency Medicine | (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ingalls Memorial Hospital | Harvey, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvey Emergency Physicians Llc | 9436486560 | 43 |
News Archive
Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June's ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.
Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.
› Verified 4 days ago
| Entity Name | Hoopeston Emergency Medicine Specialists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316965197 PECOS PAC ID: 0941102446 Enrollment ID: O20040124000083 |
News Archive
Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June's ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.
Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.
› Verified 4 days ago
| Entity Name | Epmg Of Illinois Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528098902 PECOS PAC ID: 1254225345 Enrollment ID: O20081014000533 |
News Archive
Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June's ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.
Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.
› Verified 4 days ago
| Entity Name | Harvey Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184281651 PECOS PAC ID: 9436486560 Enrollment ID: O20190812001944 |
News Archive
Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June's ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.
Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Schmitt, MD 75 Remit Drive, Lockbox 6322, Chicago, IL 60675-6322 Ph: (866) 916-5259 | Richard Schmitt, MD 3 Erie Ct, Oak Park, IL 60302-2519 Ph: (708) 383-6200 |
News Archive
Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June's ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.
Zyga Technology announced today that it had raised $25 million in a Series C financing led by new investor Versant Ventures of Menlo Park, California. Joining Versant in this round are existing investors Split Rock Partners, Domain Associates, and MB Venture Partners. With this investment, Kirk Nielsen, Managing Director, Versant Ventures will join the board of directors of Zyga.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.
BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.
› Verified 4 days ago
Dr. Katrina Weimer, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 14 Lake St, Oak Park, IL 60302 Phone: 708-383-0113 | |
Nupur Shah, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S Maple Ave, Oak Park, IL 60304 Phone: 708-660-5997 | |
Steven Ross, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3 Erie Ct, Oak Park, IL 60302 Phone: 708-383-6200 | |
Dr. Colin Therriault, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 520 S Maple Ave, Oak Park, IL 60304 Phone: 708-660-5997 | |
Steven Rockoff, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3 Erie Ct, Oak Park, IL 60302 Phone: 708-383-6200 | |
Dr. David Manno, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 Lake St Ste 125b, Oak Park, IL 60301 Phone: 708-334-8075 |